




March 2006 Update

NAV/share (06/03/06): EUR 133.97

ISIN code: LU0141953439

website: www.citadelfund.com



Citadel Value Fund Performance
(as of March 6th, 2006)

	Since inception (11/02/02)	3 year	1 year	2006* YTD
Citadel Value Fund	34.0%	84.1%	10.6%	7.0%
MSCI World Index	8.4%	72.9%	23.8%	2.5%

note: MSCI World Index is based on total returns in Euro's

* annual returns are based on estimated NAV as of Dec. 31, 2002/03/04 & 05

source: European Fund Administration, MSCI

Top 10 holdings

Telegraaf Media Groep NV	7.5%
Heineken Holding NV	6.2%
Lambert Howarth PLC	5.8%
Wegener NV	5.0%
Bristol-Myers Squibb Co.	4.9%
Ultraframe PLC	4.5%
Batenburg Beheer NV	4.5%
Village Super Market Inc.	4.4%
Wolters Kluwer NV	4.0%
Nedschroef Holding NV	4.1%

COMMENTARY

Since the last update a month ago, Citadel's NAV rose by 2.2% to March 6th bringing the Fund's performance since inception to 34%. Global equities (MSCI World Index) rose by 8.4% during the same period.

Our optimism concerning the Fund's media holdings received a further boost after **Axel Springer** reported a 38%! jump in operating profits despite sluggish advertising markets. **Wolters Kluwer** also presented improved results and the stock reflects this, rising by more than a quarter this year. We added substantially to the position in **Telegraaf**. The share price had barely budged despite a number of clearly positive developments. The company's 25% stake (to be sold) in **Wegener** has increased in value by more than 30% this year. Furthermore there are at least 3 parties interested in one of its larger regional papers. Not only do the chances of a sale at an attractive price appear good, but a sale would also highlight the cheapness of its remaining (arguably superior) assets. Another change in the portfolio was the sale of the stake in **Merck & Co**. The stock has jumped by 30%+ in 2006 after the firm gave an optimistic update on its drug pipeline and cost savings, in addition to winning a 2nd **Vioxx** case. Merck is certainly not overvalued on a LT view. However, and this was the reason for selling, the stock's run-up appears premature given the almost inevitable future litigation setbacks and a weak ST outlook. The position generated a return of 22% which was decent, considering that the bulk of the investment occurred in the past 18 months. Finally, Citadel's two brewers had a good month. **Grolsch** announced a key distribution deal in the US with Anheuser Busch, and **Heineken** revealed plans to cut EUR 200m in costs and launch *Heineken Light* in the US.

IMPORTANT: An investment in the Fund carries with it a degree of risk. The value of your investment may go down as well as up, and you could lose money on your investment. Past performance provides no guarantee for the future. Investors should read the Fund's prospectus before deciding whether to invest. The opinions and commentary expressed herein should in no way be construed as personal investment advice, they are intended solely to illustrate the Fund's investment strategy and performance.